Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data

Neumora Therapeutics, Inc.

FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.
Approximately 30 participants dosed in study; no convulsions observed in any participant.
Company working with FDA to evaluate resolving the hold; prior guidance on NMRA-266 withdrawn.
NMRA-266 is an M4 muscarinic receptor PAM, part of Neumora's M4 PAM franchise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.